Abstract
To test the functional consequences of blocking the local renin-angiotensin system (RAS), we investigated the effects of an angiotensin II type 1 receptor blocker (ARB), candesartan, on the systemic gene expression profile of five important organs (brain, heart, kidney, liver and adipose tissues) in the stroke-prone spontaneously hypertensive rat (SHRSP), an established model of essential hypertension and cardiovascular disorders, and its normotensive control, the Wistar Kyoto (WKY) rat. Rats were treated with candesartan (5 mg/kg/d) for 4 weeks from 12 to 16 weeks of age. DNA microarray technology was used to identify changes in gene expression. Four weeks of treatment with candesartan significantly lowered systolic blood pressure in male rats of both the SHRSP and the WKY strains (p<0.0005). Candesartan differentially modulated the gene expression profile in an organ-specific manner in male SHRSP; of the five organs tested, gene expression was most prominently altered in the hearts of SHRSP. In contrast, candesartan treatment exerted minimal or no significant effects on the gene expression profile of the corresponding organs of male WKY rats. The inter-strain differences in gene expression changes induced by candesartan were considered to be associated with both blood pressure–dependent and independent mechanisms. These results help to delineate the mechanisms that underlie the organ or tissue protection conferred by ARB at the levels of cellular biology and genomics in the context of the local RAS. Further studies are warranted to investigate not only individual genes of interest but also genetic “networks” that involve differential organ- or tissue-specific gene expression induced by the blockade of RAS in essential hypertension.
Similar content being viewed by others
Article PDF
References
Danser AH : Local renin-angiotensin systems: the unanswered questions. Int J Biochem Cell Biol 2003; 35: 759–768.
Kobori H, Nangaku M, Navar LG, Nishiyama A : The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007; 59: 251–287.
Chrysant SG : The pathophysiologic role of the brain reninangiotensin system in stroke protection: clinical implications. J Clin Hypertens 2007; 9: 454–459.
Bader M : Role of the local renin-angiotensin system in cardiac damage: a minireview focussing on transgenic animal models. J Mol Cell Cardiol 2002; 34: 1455–1462.
Paul M, Poyan Mehr A, Kreutz R : Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86: 747–803.
Ferreira JC, Bacurau AV, Evangelista FS, et al: The role of local and systemic renin angiotensin system activation in a genetic model of sympathetic hyperactivity–induced heart failure in mice. Am J Physiol Regul Integr Comp Physiol 2008; 294: R26–R32.
Zhou J, Pavel J, Macova M, et al: AT1 receptor blockade regulates the local angiotensin II system in cerebral microvessels from spontaneously hypertensive rats. Stroke 2006; 37: 1271–1276.
Dzau V : The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens Suppl 2005; 23: S9–S17.
Kato N, Mashimo T, Nabika T, Cui ZH, Ikeda K, Yamori Y : Genome-wide searches for blood pressure quantitative trait loci in the stroke-prone spontaneously hypertensive rat of a Japanese colony. J Hypertens 2003; 21: 295–303.
Hamaya Y, Takeda T, Dohi S, Nakashima S, Nozawa Y : The effects of pentobarbital, isoflurane, and propofol on immediate-early gene expression in the vital organs of the rat. Anesth Analg 2000; 90: 1177–1183.
Hu J, Gray CA, Spencer TE : Gene expression profiling of neonatal mouse uterine development. Biol Reprod 2004; 70: 1870–1876.
Davidson LA, Nguyen DV, Hokanson RM, et al: Chemopreventive n-3 polyunsaturated fatty acids reprogram genetic signatures during colon cancer initiation and progression in the rat. Cancer Res 2004; 64: 6797–6804.
Ramakrishnan R, Dorris D, Lublinsky A, et al: An assessment of Motorola CodeLink microarray performance for gene expression profiling applications. Nucleic Acids Res 2002; 30: e30.
Treister NS, Richards SM, Suzuki T, Jensen RV, Sullivan DA : Influence of androgens on gene expression in the BALB/c mouse submandibular gland. J Dent Res 2005; 84: 1187–1192.
Kato N, Liang YQ, Ochiai Y, Jesmin S : Systemic evaluation of gene expression changes in major target organs induced by atorvastatin. Eur J Pharmacol 2008; 584: 376–389.
Ashburner M, Ball CA, Blake JA, et al: Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000; 25: 25–29.
Hwang DM, Dempsey AA, Wang RX, et al: A genomebased resource for molecular cardiovascular medicine: toward a compendium of cardiovascular genes. Circulation 1997; 96: 4146–4203.
Varagic J, Frohlich ED : Local cardiac renin-angiotensin system: hypertension and cardiac failure. J Mol Cell Cardiol 2002; 34: 1435–1442.
Dendorfer A, Dominiak P, Schunkert H : ACE inhibitors and angiotensin II receptor antagonists. Handb Exp Pharmacol 2005; 170: 407–442.
Takai S, Kirimura K, Jin D, et al: Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling. Hypertens Res 2005; 28: 593–600.
Yamamoto K, Mano T, Yoshida J, et al: ACE inhibitor and angiotensin II type 1 receptor blocker differently regulate ventricular fibrosis in hypertensive diastolic heart failure. J Hypertens 2005; 23: 393–400.
Kim S, Yoshiyama M, Izumi Y, et al: Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. Circulation 2001; 103: 148–154.
Ito T, Yamakawa H, Bregonzio C, Terrón JA, Falcón-Neri A, Saavedra JM : Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. Stroke 2002; 33: 2297–2303.
Zhou J, Jezova M, Elkahloun AG, Saavedra JM : Angiotensin II AT1 receptor antagonism downregulates stressrelated gene expression in brain microvessels from spontaneously hypertensive and normotensive rats. Ann N Y Acad Sci 2004; 1018: 480–486.
Lu Q, Zhu YZ, Wong PT : Neuroprotective effects of candesartan against cerebral ischemia in spontaneously hypertensive rats. Neuroreport 2005; 16: 1963–1967.
Collison M, Glazier AM, Graham D, et al: Cd36 and molecular mechanisms of insulin resistance in the stroke-prone spontaneously hypertensive rat. Diabetes 2000; 49: 2222–2226.
Kim S, Soltani-Bejnood M, Quignard-Boulange A, et al: The adipose renin-angiotensin system modulates systemic markers of insulin sensitivity and activates the intrarenal renin-angiotensin system. J Biomed Biotechnol 2006; 2006: 27012.
Sharma AM, Engeli S : The role of renin-angiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome. J Cardiometab Syndr 2006; 1: 29–35.
Staessen JA, Li Y, Thijs L, Wang JG : Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trials. Hypertens Res 2005; 28: 385–407.
Lazartigues E, Feng Y, Lavoie JL : The two fACEs of the tissue renin-angiotensin systems: implication in cardiovascular diseases. Curr Pharm Des 2007; 13: 1231–1245.
Engeli S, Schling P, Gorzelniak K, et al: The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol 2003; 35: 807–825.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kato, N., Liang, YQ., Ochiai, Y. et al. Candesartan-Induced Gene Expression in Five Organs of Stroke-Prone Spontaneously Hypertensive Rats. Hypertens Res 31, 1963–1975 (2008). https://doi.org/10.1291/hypres.31.1963
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.31.1963